Literature DB >> 12207349

Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes.

Carel A van Baalen1, Christophe Guillon, Minus van Baalen, Esther J Verschuren, Patrick H M Boers, Albert D M E Osterhaus, Rob A Gruters.   

Abstract

Recent studies indicate that the time required for virus-infected cells to become vulnerable for the activity of CTL is of significance for the capacity of CTL to control ongoing viral reproduction. To investigate whether this applies to the effectiveness of HIV-1-specific CTL, we measured virus production in cultures containing CD4(+) T cells inoculated with HIV at low multiplicity of infection, and CTL directed against an early protein, Rev, or a late protein, RT. The Rev-specific CTL prevented at least 2 log(10) more HIV-1 production, in 10 days, than similar numbers of RT-specific CTL. To study how CTL effectiveness depends on variations in the potency of effector functions and kinetics of HIV protein expression, we developed a mathematical model describing CTL-target cell interactions during successive infection cycles. The results show that substantially higher CTL-mediated target cell elimination rates are required to achieve control as there is less time for CTL to act before infected cells release progeny virions. Furthermore, in vitro experiments with HIV recombinant viruses showed that the RT-specific CTL were at least as effective as the Rev-specific CTL, but only if the RT epitope was expressed as part of the early protein Nef. Together these results indicate that CTL control ongoing HIV reproduction more effectively if they are able to recognize infected cells earlier during individual viral replication cycles. This provides rationale for immunization strategies that aim at inducing, boosting or skewing CTL responses to early regulatory proteins in AIDS vaccine development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12207349     DOI: 10.1002/1521-4141(200209)32:9<2644::AID-IMMU2644>3.0.CO;2-R

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  31 in total

1.  Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response.

Authors:  Thomas C Friedrich; Christopher A Frye; Levi J Yant; David H O'Connor; Nancy A Kriewaldt; Meghan Benson; Lara Vojnov; Elizabeth J Dodds; Candice Cullen; Richard Rudersdorf; Austin L Hughes; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Impaired immune evasion in HIV through intracellular delays and multiple infection of cells.

Authors:  Christian L Althaus; Rob J De Boer
Journal:  Proc Biol Sci       Date:  2012-04-04       Impact factor: 5.349

3.  Tat(28-35)SL8-specific CD8+ T lymphocytes are more effective than Gag(181-189)CM9-specific CD8+ T lymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay.

Authors:  John T Loffredo; Eva G Rakasz; Juan Pablo Giraldo; Sean P Spencer; Kelly K Grafton; Sarah R Martin; Gnankang Napoé; Levi J Yant; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Rapid recruitment of virus-specific CD8 T cells restructures immunodominance during protective secondary responses.

Authors:  Anne E Tebo; Michael J Fuller; Dalia E Gaddis; Kyoko Kojima; Kunal Rehani; Allan J Zajac
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression.

Authors:  Jonah B Sacha; Chungwon Chung; Eva G Rakasz; Sean P Spencer; Anna K Jonas; Alexander T Bean; Wonhee Lee; Benjamin J Burwitz; Jason J Stephany; John T Loffredo; David B Allison; Sama Adnan; Akihiko Hoji; Nancy A Wilson; Thomas C Friedrich; Jeffrey D Lifson; Otto O Yang; David I Watkins
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

6.  Pol-specific CD8+ T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I downregulation.

Authors:  Jonah B Sacha; Chungwon Chung; Jason Reed; Anna K Jonas; Alexander T Bean; Sean P Spencer; Wonhee Lee; Lara Vojnov; Richard Rudersdorf; Thomas C Friedrich; Nancy A Wilson; Jeffrey D Lifson; David I Watkins
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

7.  Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes.

Authors:  Diana Y Chen; Arumugam Balamurugan; Hwee L Ng; William G Cumberland; Otto O Yang
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

8.  Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic.

Authors:  Lara Vojnov; Jason S Reed; Kim L Weisgrau; Eva G Rakasz; John T Loffredo; Shari M Piaskowski; Jonah B Sacha; Holly L Kolar; Nancy A Wilson; R Paul Johnson; David I Watkins
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239.

Authors:  Nancy A Wilson; Jason Reed; Gnankang S Napoe; Shari Piaskowski; Andy Szymanski; Jessica Furlott; Edna J Gonzalez; Levi J Yant; Nicholas J Maness; Gemma E May; Taeko Soma; Matthew R Reynolds; Eva Rakasz; Richard Rudersdorf; Adrian B McDermott; David H O'Connor; Thomas C Friedrich; David B Allison; Amit Patki; Louis J Picker; Dennis R Burton; Jing Lin; Lingyi Huang; Deepa Patel; Gwendolyn Heindecker; Jiang Fan; Michael Citron; Melanie Horton; Fubao Wang; Xiaoping Liang; John W Shiver; Danilo R Casimiro; David I Watkins
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

10.  HLA class I binding of HBZ determines outcome in HTLV-1 infection.

Authors:  Aidan Macnamara; Aileen Rowan; Silva Hilburn; Ulrich Kadolsky; Hiroshi Fujiwara; Koichiro Suemori; Masaki Yasukawa; Graham Taylor; Charles R M Bangham; Becca Asquith
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.